StockpollyBeta
Get App
Popularity #3,483
BNTC · NASDAQ · Biotechnology

Benitec Biopharma (BNTC)

Develops BB-301, a ddRNAi genetic medicine for OPMD dysphagia.

$9.92
vs last close−1.03 (−9.43%)

  1. Benitec Biopharma (BNTC) Projected to Release Quarterly Earnings on Monday

    Defense World

  2. Benitec Biopharma Releases Full Year 2026 Financial Results and Provides Operational Update

    GlobeNewsWire

  3. AWM Investment Company Inc. Acquires New Position in Benitec Biopharma Limited $BNTC

    Defense WorldOwnership

  4. Benitec Biopharma Releases Third Quarter 2026 Financial Results and Provides Operational Update

    GlobeNewsWire

  5. Benitec Biopharma Announces Oral Presentation of Interim Phase 1b/2a Clinical Study Results for High Dose BB-301 and Continued Durable Improvements for Low Dose BB-301 at the 2026 American Society of Gene and Cell Therapy Annual Meeting

    GlobeNewsWire

  6. Benitec Biopharma to Host Industry Forum Breakfast Event at the 2026 Muscular Dystrophy Association Clinical and Scientific Conference on March 10, 2026, Highlighting Continued Progress for BB-301, the Only Clinical-Stage Therapeutic in Development for Oculopharyngeal Muscular Dystrophy (OPMD)

    GlobeNewsWire

  7. Benitec Biopharma Announces Acceptance of Late- Breaking Abstract for the BB-301 Phase 1b/2a Clinical Treatment Study at the Muscular Dystrophy Association Clinical & Scientific Conference

    Globe News Wire

  8. Benitec Biopharma: BB-301's Early OPMD Data And Cash Infusion Justify A Bullish Upgrade

    Seeking Alpha

  9. Benitec Biopharma Provides Positive Long-Term Clinical Study Results for BB-301 Phase 1b/2a Clinical Trial Demonstrating Robust Efficacy and Continued Durability of Response

    GlobeNewsWire

  10. Benitec Biopharma (NASDAQ:BNTC) Director Suvretta Capital Management, L Buys 16,836 Shares

    Defense World

  11. Benitec Biopharma (NASDAQ:BNTC) Director Suvretta Capital Management, L Acquires 50,000 Shares

    Defense World

  12. Does Benitec Biopharma (BNTC) Have the Potential to Rally 83.87% as Wall Street Analysts Expect?

    Zacks Investment Research

  13. Benitec Biopharma (NASDAQ:BNTC) Director Suvretta Capital Management, L Purchases 10,215 Shares of Stock

    Defense World

  14. Wall Street Analysts Predict an 87.48% Upside in Benitec Biopharma (BNTC): Here's What You Should Know

    Zacks Investment Research

  15. Down 25.8% in 4 Weeks, Here's Why You Should You Buy the Dip in Benitec Biopharma (BNTC)

    Zacks Investment Research

  16. Benitec Biopharma Releases First Quarter 2026 Financial Results and Provides Operational Update

    GlobeNewsWire

  17. Big Insider Purchases by Carl Icahn, Mario Gabelli, and Others

    24/7 Wall Street

  18. Benitec Biopharma Inc. Announces Pricing of $100 Million Common Stock Offering

    GlobeNewsWire

  19. Benitec Biopharma Inc. Announces Proposed Public Offering

    GlobeNewsWire

  20. Benitec Biopharma to Provide Phase 1b/2a Clinical Study Update for BB-301 in Oculopharyngeal Muscular Dystrophy

    GlobeNewsWire

  21. Benitec Biopharma Limited (NASDAQ:BNTC) Given Consensus Rating of “Moderate Buy” by Analysts

    Defense World

  22. Benitec Biopharma Releases Full Year 2025 Financial Results and Provides Operational Update

    GlobeNewsWire

  23. Benitec Biopharma (BNTC) is on the Move, Here's Why the Trend Could be Sustainable

    Zacks Investment Research

  24. Wall Street Analysts See a 65.98% Upside in Benitec Biopharma (BNTC): Can the Stock Really Move This High?

    Zacks Investment Research